Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19

BACKGROUND: Garadacimab, a fully human IgG4 monoclonal antibody, inhibits the kallikrein–kinin pathway at a key initiator, activated coagulation factor XII (FXIIa), and may play a protective role in preventing the progression of COVID-19. This phase 2 study evaluated the efficacy and safety of garad...

Descripción completa

Detalles Bibliográficos
Autores principales: Papi, Alberto, Stapleton, Renee D., Shore, Paul M., Bica, Mihai Alexandru, Chen, Younan, Larbig, Michael, Welte, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064633/
https://www.ncbi.nlm.nih.gov/pubmed/37000214
http://dx.doi.org/10.1007/s00408-023-00615-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064633/
https://www.ncbi.nlm.nih.gov/pubmed/37000214
http://dx.doi.org/10.1007/s00408-023-00615-9

Ejemplares similares